<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">TCM</journal-id><journal-title-group><journal-title>Traditional Chinese Medicine</journal-title></journal-title-group><issn pub-type="epub">2166-6067</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/TCM.2020.91006</article-id><article-id pub-id-type="publisher-id">TCM-33983</article-id><article-categories><subj-group subj-group-type="heading"><subject>TCM20200100000_76442821.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  三氧化二砷治疗原发性肝细胞癌的实验及临床研究进展
  Experimental and Clinical Research Progress of Arsenic Trioxide in Treating Hepatocellular Carcinoma
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>万</surname><given-names>迁迁</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>万</surname><given-names>旭英</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>海军军医大学第三附属医院中西医结合科，上海</addr-line></aff><aff id="aff2"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>31</day><month>12</month><year>2019</year></pub-date><volume>09</volume><issue>01</issue><fpage>34</fpage><lpage>39</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   原发性肝细胞癌(Hepatocellular Carcinoma, HCC)的发病率在全世界呈上升趋势，三氧化二砷(Arsenic trioxide, As<sub>2</sub>O<sub>3</sub>)，作为一种中药单体，已经被大量用于HCC的实验及临床研究。但仍需要大样本的临床研究来明确其临床疗效，仍有必要进行As2O3联合TACE、化疗药物及靶向药物等治疗原发性肝癌的临床研究。&lt;br/&gt;The incidence of Hepatocellular Carcinoma (HCC) is on the rise worldwide. Arsenic trioxide (As<sub>2</sub>O<sub>3</sub>), as a monomer of traditional Chinese medicine, has been widely used in experimental and clinical studies of HCC. However, large samples of clinical studies are still needed to clarify its clinical efficacy, and clinical studies on combination of As2O3 with TACE, chemotherapy drugs and targeted drugs for the treatment of primary liver cancer are still necessary. 
  
 
</p></abstract><kwd-group><kwd>原发性肝细胞癌，三氧化二砷，研究进展, Hepatocellular Carcinoma</kwd><kwd> Arsenic Trioxide</kwd><kwd> Research Progress</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>三氧化二砷治疗原发性肝细胞癌的 实验及临床研究进展<sup> </sup></title><p>万迁迁，万旭英<sup>*</sup></p><p>海军军医大学第三附属医院中西医结合科，上海</p><disp-formula id="hanspub.33983-formula51"><graphic xlink:href="//html.hanspub.org/file/6-2270496x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2019年12月10日；录用日期：2020年1月9日；发布日期：2020年1月16日</p><disp-formula id="hanspub.33983-formula52"><graphic xlink:href="//html.hanspub.org/file/6-2270496x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>原发性肝细胞癌(Hepatocellular Carcinoma, HCC)的发病率在全世界呈上升趋势，三氧化二砷(Arsenic trioxide, As<sub>2</sub>O<sub>3</sub>)，作为一种中药单体，已经被大量用于HCC的实验及临床研究。但仍需要大样本的临床研究来明确其临床疗效，仍有必要进行As<sub>2</sub>O<sub>3</sub>联合TACE、化疗药物及靶向药物等治疗原发性肝癌的临床研究。</p><p>关键词 :原发性肝细胞癌，三氧化二砷，研究进展</p><disp-formula id="hanspub.33983-formula53"><graphic xlink:href="//html.hanspub.org/file/6-2270496x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/6-2270496x8_hanspub.png" /> <img src="//html.hanspub.org/file/6-2270496x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>原发性肝癌(Hepatocellular Carcinoma, HCC)的发病率在全世界呈上升趋势，是导致全球癌症死亡的主要原因之一 [<xref ref-type="bibr" rid="hanspub.33983-ref1">1</xref>]。手术切除仍为HCC的主要治疗手段 [<xref ref-type="bibr" rid="hanspub.33983-ref2">2</xref>]，但很大一部分病人在发现肝肿瘤时已处于中晚期，并丧失手术机会。近三十年来，药物性全身治疗HCC得到了快速的发展，索拉菲尼、仑伐替尼已作为晚期HCC的一线治疗 [<xref ref-type="bibr" rid="hanspub.33983-ref3">3</xref>]。三氧化二砷(Arsenic trioxide, As<sub>2</sub>O<sub>3</sub>)，也就是砒霜，最早用于治疗白血病 [<xref ref-type="bibr" rid="hanspub.33983-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.33983-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.33983-ref6">6</xref>]，九十年代开始用于治疗原发性肝癌 [<xref ref-type="bibr" rid="hanspub.33983-ref7">7</xref>]。As<sub>2</sub>O<sub>3</sub>作为一种中药单体，已经被大量用于HCC的实验及临床研究 [<xref ref-type="bibr" rid="hanspub.33983-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.33983-ref9">9</xref>]，现将近年来关于As<sub>2</sub>O<sub>3</sub>治疗HCC的实验及临床研究综述如下。</p></sec><sec id="s4"><title>2. 实验研究</title><p>近年来实验研究表明，As<sub>2</sub>O<sub>3</sub>治疗原发性肝癌的机制主要包括抑制肿瘤细胞增殖、促进细胞凋亡、抑制肿瘤内皮和血管生成等方面 [<xref ref-type="bibr" rid="hanspub.33983-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.33983-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.33983-ref12">12</xref>]。</p><sec id="s4_1"><title>2.1. As<sub>2</sub>O<sub>3</sub>抑制肿瘤细胞增殖</title><p>自上世纪九十年代李琳等人开始将As<sub>2</sub>O<sub>3</sub>用于原发性肝癌的研究，目前已经有大量的实验研究发现As<sub>2</sub>O<sub>3</sub>抑制肿瘤细胞增殖、转移等方面有明确的效果。例如，李海燕发现As<sub>2</sub>O<sub>3</sub>对肿瘤细胞增殖有抑制作用，并且以2.0 μmol/L剂量时作用最强 [<xref ref-type="bibr" rid="hanspub.33983-ref13">13</xref>]。金洲祥 [<xref ref-type="bibr" rid="hanspub.33983-ref14">14</xref>] 通过研究不同浓度As<sub>2</sub>O<sub>3</sub>联合5-氟尿嘧啶(5-FU)对小鼠肝癌H22细胞株的抑制作用，发现在体外As<sub>2</sub>O<sub>3</sub>和5-FU对小鼠肝癌H22细胞有明显地抑制增殖和诱导凋亡的作用。刘玉 [<xref ref-type="bibr" rid="hanspub.33983-ref15">15</xref>] 通过研究小剂量As<sub>2</sub>O<sub>3</sub>联合3’-叠氮-3’-脱氧胸腺嘧啶核苷(3’-azido3’-deoxythymidine, AZT)对肝癌HepG2细胞增殖和凋亡的作用及其可能的作用机制，发现As<sub>2</sub>O<sub>3</sub>联合AZT可以协同抑制HepG2细胞的增殖。嵇静 [<xref ref-type="bibr" rid="hanspub.33983-ref16">16</xref>] 通过研究As<sub>2</sub>O<sub>3</sub>和顺铂联合应用对人肝癌HepG2细胞株的作用，发现在体外，联合应用两种药物可以起到明显的协同抗肝癌作用、抑制人肝癌HepG2细胞株的生长，并呈明显的剂量时效关系。</p></sec><sec id="s4_2"><title>2.2. As<sub>2</sub>O<sub>3</sub>促进肿瘤细胞凋亡</title><p>研究发现，As<sub>2</sub>O<sub>3</sub>可以诱导肝癌细胞凋亡，抑制肝癌细胞生长 [<xref ref-type="bibr" rid="hanspub.33983-ref17">17</xref>]。目前主要认为其通过活性氧和氧化应激诱导肝癌细胞的凋亡。有研究认为其主要表现为诱导ROS、gamma-GCS表达抑制、下调细胞谷胱甘肽含量，来诱导人肝癌细胞HepG2凋亡 [<xref ref-type="bibr" rid="hanspub.33983-ref18">18</xref>]。于浩 [<xref ref-type="bibr" rid="hanspub.33983-ref19">19</xref>] 通过观察As<sub>2</sub>O<sub>3</sub>对肝癌细胞系HepG2和Huh-7的影响，发现As<sub>2</sub>O<sub>3</sub>对肝癌细胞HepG2和Huh-7具有诱导凋亡的作用。温焕连通过研究As<sub>2</sub>O<sub>3</sub>联合顺铂(GDDP)对肝癌HepG2细胞的作用，发现As<sub>2</sub>O<sub>3</sub>联合化疗能诱导肝细胞的凋亡。亦有研究将As<sub>2</sub>O<sub>3</sub>与索拉非尼联合应用于肝癌细胞系Huh-7和新分离的肝癌细胞，发现其具有强大的抗肿瘤活性 [<xref ref-type="bibr" rid="hanspub.33983-ref20">20</xref>]。</p></sec><sec id="s4_3"><title>2.3. As<sub>2</sub>O<sub>3</sub>抑制肿瘤内皮和血管生成</title><p>段建华 [<xref ref-type="bibr" rid="hanspub.33983-ref21">21</xref>] 通过研究As<sub>2</sub>O<sub>3</sub>对人肝癌细胞株的作用及其可能机制，发现As<sub>2</sub>O<sub>3</sub>可有效抑制人肝癌细胞的生长增殖，其机制可能与诱导细胞凋亡、阻滞细胞周期及。宋海林 [<xref ref-type="bibr" rid="hanspub.33983-ref22">22</xref>] 通过研究As<sub>2</sub>O<sub>3</sub>对肝癌HepG2细胞血管生成拟态(VM)形成的影响，发现As<sub>2</sub>O<sub>3</sub>抑制HepG2细胞形成VM，其作用机制可能与抑制拟态通路相关蛋白VE-cadherin和MMP-2的表达有关。高明等 [<xref ref-type="bibr" rid="hanspub.33983-ref23">23</xref>] 的研究亦发现高浓度的三氧化二砷(5.0 umol/L)可刺激VEGF mRNA的表达。</p></sec></sec><sec id="s5"><title>3. 临床研究</title><p>As<sub>2</sub>O<sub>3</sub>是一种安全有效的药物，其治疗中晚期原发性肝癌已经广泛应用在临床上，主要治疗方式包括As<sub>2</sub>O<sub>3</sub>单药静脉注射、As<sub>2</sub>O<sub>3</sub>联合TACE、As<sub>2</sub>O<sub>3</sub>联合其他化疗、靶向药物等来治疗原发性肝癌。</p><sec id="s5_1"><title>3.1. As<sub>2</sub>O<sub>3</sub>单药治疗原发性肝癌</title><p>目前大量的临床研究表明，对于晚期原发性肝癌患者，As<sub>2</sub>O<sub>3</sub>仍不失是一种有效的治疗手段。屈凤莲 [<xref ref-type="bibr" rid="hanspub.33983-ref24">24</xref>] 通过对111例中晚期原发性肝癌患者进行研究，发现通过两个周期的亚砷酸治疗，患者临床获益率达76.5%。郭换珍 [<xref ref-type="bibr" rid="hanspub.33983-ref25">25</xref>] 通过对48例晚期原发性肝癌患者进行研究后发现，经过两个疗程的三氧化二砷治疗，治疗组患者均有一定的有效率和获益率，且生活质量得以改善。颜庆余 [<xref ref-type="bibr" rid="hanspub.33983-ref26">26</xref>] 对53例原发性肝癌患者进行As<sub>2</sub>O<sub>3</sub>治疗6个疗程后，分析发现38例肿瘤体积缩小或不变，有效率为71.6%。可见As<sub>2</sub>O<sub>3</sub>是治疗原发性肝癌的一种安全、有效的药物。亦有研究将As<sub>2</sub>O<sub>3</sub>用于治疗原发性肝癌患者14天后，发现患者体内ezrin蛋白的表达明显下降 [<xref ref-type="bibr" rid="hanspub.33983-ref27">27</xref>]。另外有研究将As<sub>2</sub>O<sub>3</sub>用于治疗有肺转移的原发性肝癌患者，发现不管是经动脉灌注栓塞给药，或是静脉注射给药，均是安全有效的治疗措施 [<xref ref-type="bibr" rid="hanspub.33983-ref28">28</xref>]。</p></sec><sec id="s5_2"><title>3.2. As<sub>2</sub>O<sub>3</sub>联合TACE治疗原发性肝癌</title><p>目前，已有大量的临床研究表明As<sub>2</sub>O<sub>3</sub>联合TACE治疗原发性肝癌是一种有效并且安全的方式 [<xref ref-type="bibr" rid="hanspub.33983-ref29">29</xref>] [<xref ref-type="bibr" rid="hanspub.33983-ref30">30</xref>] [<xref ref-type="bibr" rid="hanspub.33983-ref31">31</xref>] [<xref ref-type="bibr" rid="hanspub.33983-ref32">32</xref>]，并且能够延长患者的生存期 [<xref ref-type="bibr" rid="hanspub.33983-ref33">33</xref>]。其中，张保新 [<xref ref-type="bibr" rid="hanspub.33983-ref34">34</xref>] 将As<sub>2</sub>O<sub>3</sub>与化疗药物联合一起注入肝动脉来治疗原发性肝癌，通过与传统介入治疗对比，发现治疗组有效率为60%，获益率93.3%。他认为As<sub>2</sub>O<sub>3</sub>联合TACE治疗原发性肝癌有较好疗效，不良反应较小。汤日杰 [<xref ref-type="bibr" rid="hanspub.33983-ref35">35</xref>] 使用As<sub>2</sub>O<sub>3</sub>局部区域灌注化疗并联合TACE治疗30例原发性肝癌患者，发现TACE + As<sub>2</sub>O<sub>3</sub>连续区域化疗对HCC具有一定治疗价值，其毒副反应小，疗效确切。胡琴 [<xref ref-type="bibr" rid="hanspub.33983-ref36">36</xref>] 通过对53例原发性肝癌患者进行研究，发现As<sub>2</sub>O<sub>3</sub>联合TACE治疗原发性肝癌能提高患者生存率。有研究将TACE联合As<sub>2</sub>O<sub>3</sub>用于治疗有肺转移的原发性肝癌患者，其临床获益率高达60%，并认为TACE联合As<sub>2</sub>O<sub>3</sub>在控制肺转移及延长生存期方面，较单用TACE治疗效果好 [<xref ref-type="bibr" rid="hanspub.33983-ref37">37</xref>]。</p><p>将As<sub>2</sub>O<sub>3</sub>联合TACE治疗原发性肝癌的研究众多，目前已发表3篇关于As<sub>2</sub>O<sub>3</sub>联合TACE治疗原发性肝癌的meta分析。其中Lv [<xref ref-type="bibr" rid="hanspub.33983-ref38">38</xref>] 在2017年发表的一项关于As<sub>2</sub>O<sub>3</sub>治疗原发性肝癌的meta分析，共纳入18项研究，1412例病人。经过分析，Lv认为As<sub>2</sub>O<sub>3</sub>联合TACE组治疗原发性肝癌的有效率、一年生存率均明显高于单用TACE组。Song [<xref ref-type="bibr" rid="hanspub.33983-ref39">39</xref>] 于2018年5月也发表了As<sub>2</sub>O<sub>3</sub>联合TACE治疗不可手术的原发性肝癌的meta分析，他的meta分析较Lv纳入的研究更多，病例更多。同样的，结果显示As<sub>2</sub>O<sub>3</sub>联合TACE组治疗原发性肝癌的有效率明显高于单用TACE术组，并且该治疗组患者的总获益率、两年生存率更高，SKP评分有明显的改善。2018年6月欧东 [<xref ref-type="bibr" rid="hanspub.33983-ref40">40</xref>] 也发表了类似的meta分析，他认为As<sub>2</sub>O<sub>3</sub>联合TACE术组治疗中晚期原发性肝癌的有效率、生活质量改善率、一年生存率均明显高于单用TACE术组。</p></sec><sec id="s5_3"><title>3.3. As<sub>2</sub>O<sub>3</sub>联合化疗药物治疗原发性肝癌</title><p>临床试验表明，采用As<sub>2</sub>O<sub>3</sub>联合脱氧氟尿苷、卡铂、吡柔比星介入治疗中晚期肝癌，可有效提高临床疗效，无严重不良反应，且治疗后的肝功能情况明显优于单纯使用As<sub>2</sub>O<sub>3</sub>治疗 [<xref ref-type="bibr" rid="hanspub.33983-ref41">41</xref>]。唐鑫通过对洛铂联合三氧化二砷联合TACE治疗老年原发性肝癌的临床疗效观察，发现洛铂联合As<sub>2</sub>O<sub>3</sub>治疗老年原发性肝癌可延长患者的mPFS，不良反应可耐受，可以是治疗老年原发性肝癌的较好方案 [<xref ref-type="bibr" rid="hanspub.33983-ref42">42</xref>]。另外，Yu等人通过研究发现，As<sub>2</sub>O<sub>3</sub>联合5-FU处理导致DR5、caspase 3、caspase 8、caspase 9上调，BCL-2下调，但对DR4无影响，从而降低HBx-HepG2细胞对5-氟尿嘧啶等化疗药物的耐药性 [<xref ref-type="bibr" rid="hanspub.33983-ref43">43</xref>]。</p></sec></sec><sec id="s6"><title>4. 小结</title><p>目前已有大量关于As<sub>2</sub>O<sub>3</sub>治疗原发性肝癌的实验及临床研究，As<sub>2</sub>O<sub>3</sub>作为一种中药单体，其作用机制已经比较清晰。但仍需要大样本的临床研究来明确其临床疗效，仍有必要进行As<sub>2</sub>O<sub>3</sub>联合TACE、化疗药物及靶向药物等治疗原发性肝癌的临床研究。</p></sec><sec id="s7"><title>基金项目</title><p>国家传染病重点项目(2012ZX10002-016)；中国国家自热科学基金(81102694)。</p></sec><sec id="s8"><title>文章引用</title><p>万迁迁,万旭英. 三氧化二砷治疗原发性肝细胞癌的实验及临床研究进展Experimental and Clinical Research Progress of Arsenic Trioxide in Treating Hepatocellular Carcinoma[J]. 中医学, 2020, 09(01): 34-39. https://doi.org/10.12677/TCM.2020.91006</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.33983-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Vogel, A., Cervantes, A., Chau, I., Daniele, B., Llovet, J., Meyer, T., Nault, J.C., Neumann, U., Ricke, J., Sangro, B., Schirmacher, P., Verslype, C., Zech, C.J., Arnold, D. and Martinelli, E. (2018) Hepatocellular Carcinoma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 29, iv238-iv55. &lt;br&gt;https://doi.org/10.1093/annonc/mdy308</mixed-citation></ref><ref id="hanspub.33983-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">余炯杰, 严文韬, 权冰, 杨田. “2018年欧洲肝病学会临床实践指南: 肝细胞癌的管理”推荐意见[J]. 临床肝胆病杂志, 2018, 34(6): 1183-1186.</mixed-citation></ref><ref id="hanspub.33983-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">葛宁灵, 薛同春, 叶胜龙. “2018年欧洲肝病学会临床实践指南: 肝细胞癌的管理”解读[J]. 临床肝胆病杂志, 2018, 34(6): 1187-1190.</mixed-citation></ref><ref id="hanspub.33983-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">倪建华, 陈国强, 沈志祥, 李秀松, 刘海卫, 黄燕婷, 方智雯, 陈赛娟, 王振义, 陈竺. 静脉滴注三氧化二砷治疗急性早幼粒细胞白血病的药代动力学分析[J]. 中华血液学杂志, 1997(5): 27-30.</mixed-citation></ref><ref id="hanspub.33983-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Shen, Z.X., Chen, G.Q., Ni, J.H., Li, X.S., Xiong, S.M., Qiu, Q.Y., Zhu, J., Tang, W., Sun, G.L., Yang, K.Q., Chen, Y., Zhou, L., Fang, Z.W., Wang, Y.T., Ma, J., Zhang, P., Zhang, T., Chen, S.J., Chen, Z. and Wang, Z.Y. (1997) Use of Arsenic Trioxide (As2O3) in the Treatment of Acute Promyelocytic Leukemia (APL): II. Clinical Efficacy and Pharmacokinetics in Relapsed Patients. Blood, 89, 3354-3360. &lt;br&gt;https://doi.org/10.1182/blood.V89.9.3354</mixed-citation></ref><ref id="hanspub.33983-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Ni, J., Chen, G., Shen, Z., Li, X., Liu, H., Huang, Y., Fang, Z., Chen, S., Wang, Z. and Chen, L. (1997) Pharmacokinetics of Intravenous Arsenic Trioxide in the Treatment of Acute Promyelocytic Leukemia. Chinese Journal of Hematology, 18, 250-253.</mixed-citation></ref><ref id="hanspub.33983-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">刘琳, 秦叔逵, 陈惠英, 王锦鸿, 陈洪, 马军, 刘文虎. 三氧化二砷选择性诱导人肝癌细胞凋亡及相关基因的实验研究[J]. 中华肝脏病杂志, 2000, 8(6): 367-379.</mixed-citation></ref><ref id="hanspub.33983-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">王纪渊, 丁国善. 三氧化二砷治疗肝癌的研究进展[J]. 中国普通外科杂志, 2014, 23(1): 102-105.</mixed-citation></ref><ref id="hanspub.33983-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">邱从坤, 陈国硕, 王忠富, 周志鹏, 汤日杰. 三氧化二砷治疗肝癌的研究进展[J]. 中华介入放射学电子杂志. 2015, 3(1): 52-55.</mixed-citation></ref><ref id="hanspub.33983-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">张靖宇, 刘宝刚. 三氧化二砷在抗肝癌中的研究进展[J]. 实用肿瘤学杂志, 2008, 22(2): 192-194.</mixed-citation></ref><ref id="hanspub.33983-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Alarifi, S., Ali, D., Alkahtani, S., Siddiqui, M.A. and Ali, B.A. (2013) Arsenic Tri-oxide-Mediated Oxidative Stress and Genotoxicity in Human Hepatocellular Carcinoma Cells. OncoTargets and therapy, 6, 75-84.  
&lt;br&gt;https://doi.org/10.2147/OTT.S38227</mixed-citation></ref><ref id="hanspub.33983-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Liu, B., Pan, S., Dong, X., Qiao, H., Jiang, H., Krissansen, G.W. and Sun, X. (2006) Opposing Effects of Arsenic Trioxide on Hepatocellular Carcinomas in Mice. Cancer Science, 97, 675-681.  
&lt;br&gt;https://doi.org/10.1111/j.1349-7006.2006.00230.x</mixed-citation></ref><ref id="hanspub.33983-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">李海燕, 曹励民, 王娟. 三氧化二砷对人肝癌SMMC-7721细胞增殖、迁移及侵袭能力的影响[J]. 中国老年学杂志, 2013, 33(11): 2572-2574.</mixed-citation></ref><ref id="hanspub.33983-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">金洲祥, 王向昱. 三氧化二砷联合5-氟尿嘧啶对小鼠肝癌H22细胞株的抑制作用[J]. 温州医学院学报, 2013, 43(10): 655-659.</mixed-citation></ref><ref id="hanspub.33983-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">刘玉. As2O3联合AZT抗HepG2细胞的协同作用研究[D]: [硕士学位论文]. 兰州: 甘肃中医药大学, 2015.</mixed-citation></ref><ref id="hanspub.33983-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">嵇静. 三氧化二砷与顺铂联用对肝癌HepG2细胞的作用[J]. 临床医药实践, 2009, 18(13): 331-333.</mixed-citation></ref><ref id="hanspub.33983-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Sadaf, N., Kumar, N., Ali, M., Ali, V., Bimal, S. and Haque, R. (2018) Arsenic Trioxide Induces Apoptosis and Inhibits the Growth of Human Liver Cancer Cells. Life Sciences, 205, 9-17. &lt;br&gt;https://doi.org/10.1016/j.lfs.2018.05.006</mixed-citation></ref><ref id="hanspub.33983-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, W., Hu, Y.N., Jiang, X.J., Chen, C.Z. and Zhang, Z.Z. (2014) The Apoptotic Mechanism of Hepatocellular Carcinoma Cell Line (HepG2) Induced by Arsenic Trioxide. Journal of Sichuan University Medical Science Edition, 45, 739-743.</mixed-citation></ref><ref id="hanspub.33983-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">于浩, 姜洪磊, 许东, 梁健. 三氧化二砷对不同肝癌细胞系凋亡的影响[J]. 生物医学工程与临床, 2016, 20(1): 83-86.</mixed-citation></ref><ref id="hanspub.33983-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Wang, L., Min, Z., Wang, X., Hu, M., Song, D., Ren, Z., Cheng, Y. and Wang, Y. (2018) Arsenic Trioxide and Sorafenib Combination Therapy for Human Hepatocellular Carcinoma Functions via up-Regulation of TNF-Related Apoptosis-Inducing Ligand. Oncology Letters, 16, 3341-3350. &lt;br&gt;https://doi.org/10.3892/ol.2018.8981</mixed-citation></ref><ref id="hanspub.33983-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">段建华, 陈鉴, 钱燕敏, 马良. 三氧化二砷对肝癌细胞表达PTTG1和VEGF的影响及其意义[J]. 国际消化病杂志, 2012, 32(2): 114-117.</mixed-citation></ref><ref id="hanspub.33983-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">宋海林, 王雪雯, 段晶晶, 周明, 杨莉. 三氧化二砷对肝癌HepG2细胞形成血管生成拟态的影响及其机制[J]. 吉林大学学报(医学版), 2014, 40(4): 715-719+914.</mixed-citation></ref><ref id="hanspub.33983-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">高明, 褚成静, 王雪雯. 不同浓度三氧化二砷对肝癌细胞生长及血管内皮生长因子表达的影响[J]. 农垦医学, 2008, 30(1): 7-9.</mixed-citation></ref><ref id="hanspub.33983-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">屈凤莲, 郝学志, 秦叔逵, 刘基巍, 隋广杰, 陈强, 屈涛, 张和平, 孙燕. 亚砷酸注射液治疗原发性肝癌的Ⅱ期多中心临床研究[J]. 中华肿瘤杂志, 2011, 33(9): 697-701.</mixed-citation></ref><ref id="hanspub.33983-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">郭换珍, 赵直光, 唐中权, 安纪红, 孟江涛, 倪文. 三氧化二砷治疗晚期原发性肝癌的临床观察[J]. 中国肝脏病杂志(电子版), 2014, 6(1): 5-7.</mixed-citation></ref><ref id="hanspub.33983-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">颜庆余, 南永红, 张建莹. 原发性肝癌应用三氧化二砷治疗的临床研究[J]. 吉林医学, 2009, 30(6): 491-492.</mixed-citation></ref><ref id="hanspub.33983-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Lu, W., Yang, C., Du, P., Zhang, J.L. and Zhang, J.C. (2017) Effects of Arsenic Trioxide on the Expression of Ezrin in Hepatocellular Carcinoma. Medicine, 96, e7602.</mixed-citation></ref><ref id="hanspub.33983-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Liu, B., Huang, J.W., Li, Y., Hu, B.S., He, X., Zhao, W., Zheng, Y.B. and Lu, L.G. (2015) Arsenic Trioxide Transarterial Chemoembolization with and without Additional Intravenous Administration of Arsenic Trioxide in Unresectable Hepatocellular Carcinoma with Lung Metastasis: A Single-Blind, Randomized Trial. Journal of Cancer Research and Clinical Oncology, 141, 1103-1108. &lt;br&gt;https://doi.org/10.1007/s00432-014-1866-1</mixed-citation></ref><ref id="hanspub.33983-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">陈宝玲, 饶荣生. 三氧化二砷治疗原发性肝癌的临床及实验研究进展[J]. 实用癌症杂志, 2008, 23(2): 218-220.</mixed-citation></ref><ref id="hanspub.33983-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">解皓, 李海涛, 吴文娟, 刘保良. 三氧化二砷治疗原发性肝癌的研究进展[J]. 河北医药, 2006, 28(3): 219-220.</mixed-citation></ref><ref id="hanspub.33983-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">肖鹏, 梅家转, 李瑞君, 白桦, 栗敏, 刘桂举. 三氧化二砷联合经导管动脉化疗栓塞术治疗晚期原发性肝癌的疗效及安全性[J]. 肿瘤基础与临床, 2017, 30(5): 398-400.</mixed-citation></ref><ref id="hanspub.33983-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">于翔, 李刚, 顾露, 谢坪. 三氧化二砷经导管肝动脉化疗栓塞介入治疗中晚期原发性肝癌临床疗效及安全性观察[J]. 实用医院临床杂志, 2017, 14(2): 49-52.</mixed-citation></ref><ref id="hanspub.33983-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Wang, H., Liu, Y., Wang, X., Liu, D., Sun, Z., Wang, C., Jin, G., Zhang, B. and Yu, S. (2015) Randomized Clinical Control Study of Locoregional Therapy Com-bined with Arsenic Trioxide for the Treatment of Hepatocellular Carcinoma. Cancer, 121, 2917-2925. &lt;br&gt;https://doi.org/10.1002/cncr.29456</mixed-citation></ref><ref id="hanspub.33983-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">张新保, 谢建功, 于永忠, 王向日, 徐雨佳, 张和平, 陈莉娟. As2O3经肝动脉介入栓塞治疗原发性肝癌的临床研究[J]. 当代医学, 2010, 16(34): 112-113+132.</mixed-citation></ref><ref id="hanspub.33983-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">汤日杰, 崔书钟, 潭志明, 王俊, 唐云强, 王家康. 化疗栓塞结合As2O3局部连续灌注治疗肝癌30例临床观察[J]. 中医药导报, 2007, 13(8): 14-15.</mixed-citation></ref><ref id="hanspub.33983-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">胡琴, 韦永明, 管睿, 宛新安, 王银华, 胡俊. TACE联合三氧化二砷治疗原发性肝癌的临床研究[J]. 现代肿瘤医学, 2014, 22(11): 2679-2681.</mixed-citation></ref><ref id="hanspub.33983-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Hu, H.T., Yao, Q.J., Meng, Y.L., Li, H.L., Zhang, H., Luo, J.P., Guo, C.Y. and Geng, X. (2017) Arsenic Trioxide Intravenous Infusion Combined with Transcatheter Arterial Chemoembolization for the Treatment of Hepatocellular Carcinoma with Pulmonary Metastasis: Long-Term Outcome Analysis. Journal of Gastroenterology and Hepatology, 32, 295-300. &lt;br&gt;https://doi.org/10.1111/jgh.13529</mixed-citation></ref><ref id="hanspub.33983-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Lv, X.H., Wang, C.H. and Xie, Y. (2017) Arsenic Trioxide Combined with Transarterial Chemoembolization for Primary Liver Cancer: A Meta-Analysis. Journal of Gastroenterology and Hepatology, 32, 1540-1547.  
&lt;br&gt;https://doi.org/10.1111/jgh.13789</mixed-citation></ref><ref id="hanspub.33983-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Song, P., Hai, Y., Ma, W., Zhao, L., Wang, X., Xie, Q., Li, Y., Wu, Z. and Li, H. (2018) Arsenic Trioxide Combined with Transarterial Chemoembolization for Unresectable Primary Hepatic Carcinoma: A Systematic Review and Meta-Analysis. Medicine, 97, e0613. &lt;br&gt;https://doi.org/10.1097/MD.0000000000010613</mixed-citation></ref><ref id="hanspub.33983-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">欧东, 陈奕霖, 付斯瑜, 罗德红, 屈天银, 李曾. 三氧化二砷联合TACE治疗中晚期原发性肝癌疗效的Meta分析[J]. 介入放射学杂志, 2018, 27(6): 523-529.</mixed-citation></ref><ref id="hanspub.33983-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">郑子瑞, 王晓辉, 王晓娟. As2O3联合FuDR、CAP、THP介入治疗中晚期肝癌的疗效对比及意义[J]. 肝脏, 2017, 22(4): 342-344.</mixed-citation></ref><ref id="hanspub.33983-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">唐鑫, 刘玉宇, 敬方园, 李玉伟. 洛铂联合三氧化二砷TACE治疗老年原发性肝癌的临床疗效观察[J]. 介入放射学杂志, 2017, 26(12): 1136-1139.</mixed-citation></ref><ref id="hanspub.33983-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Yu, G., Chen, X., Chen, S., Ye, W., Hou, K. and Liang, M. (2015) Arsenic Trioxide Reduces Chemo-Resistance to 5-Fluorouracil and Cisplatin in HBx-HepG2 Cells via Complex Mechanisms. Cancer Cell International, 15, 116.  
&lt;br&gt;https://doi.org/10.1186/s12935-015-0269-y</mixed-citation></ref></ref-list></back></article>